More than 9 out of 10 patients are covered for ZENPEP4,5§
- Commercial insurance: 92%; Medicare insurance: 95%
§ Data are not a guarantee of coverage, or partial or full payment, by any payers listed. Actual benefits determined by respective plan administrators. Insurer plans, coverage criteria, and formularies are subject to change without notice. Check each patient’s coverage with applicable insurer. Nestlé Health Science does not endorse any individual plans. Formulary coverage does not imply efficacy or safety.
References: 1. ZENPEP. Package insert. Nestlé Health Science; 2020. 2. Wooldridge JL, Heubi JE, Amaro-Galvez R, et al. EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency. J Cyst Fibros. 2009;8(6):405-417. doi:10.1016/j.jcf.2009.07.006 3. Karnik NP, Jan A. Pancrelipase. NCBI Bookshelf. Updated April 21, 2020. Accessed November 9, 2020. www.ncbi.nlm.nih.gov/books/NBK534847 4. MMIT Data on File. Nestlé Health Science. Accessed February 1, 2021. 5. MMIT Data on File. Nestlé Health Science. Accessed November 3, 2020.